Human Calcitonin Administered by the Nasal Route: Bioavailability of Different Formulations and Efficacy in Post-Menopausal Osteoporosis
After its discovery by Copp et al. in 1962, calcitonin has been employed in the management of several bone diseases, for instance postmenopausal osteoporosis and Paget’s disease. Treatment of the above disease requires i.m. or s.c. administrations daily or on alternate days for prolonged periods, and this can reduce patient compliance during the course of the disease (Stevenson et al., 1981).
KeywordsPostmenopausal Osteoporosis Intranasal Administration Salmon Calcitonin Spray Solution Human Calcitonin
Unable to display preview. Download preview PDF.
- Ziegler R., Holz G., Raue F., and Streibl W., 1979, Nasal application of human calcitonin in Paaet’s disease of bone., Mol. Endocrinoi. 1: 293.Google Scholar